Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
d with excessiveinflammation including osteoarthritis and rheumatoid arthritis. For moreinformation on Logical Therapeutics visit the company's website at http://www.logicaltherapeutics.com or send an email toinfo@logicaltherapeutics.com
Date:9/8/2008